Global Gynecological Cancers Therapeutics Market Forecast 2019-2023, with AstraZeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, GlaxoSmithKline, Merck & Co. Dominating - ResearchAndMarkets.com

The "Global
Gynecological Cancers Therapeutics Market 2019-2023" report has
been added to ResearchAndMarkets.com's offering.

The gynecological cancer's therapeutics market will register a CAGR of
over 14% by 2023.

The incidence of gynecological cancers such as cervical, uterine, and
ovarian cancer is dramatically increasing throughout the world. The
increasing incidence can be attributed to risk factors such as obesity,
viral infections, smoking, and immune system deficiency.

Regional disparities exist in the incidence of gynecological cancers. In
low and middle-income countries. the incidence of gynecological cancers
is increasing due to the non-availability of or limited access to
advanced diagnostic facilities.

Strong pipeline and new drug approval

The pipeline for the treatment of gynecological cancers includes, novel
therapeutics, which such as vaccines, gene therapy and targeted therapy
products. Targeted therapy products and vaccines are in the later stages
of clinical development and some of them are even expected to be
launched during the forecast period.

High cost of treatment

The direct costs associated with the initial screening, diagnostic
procedures, counseling, outpatient visits, surgery, inpatient charges,
palliative care, and emergency services as well as the indirect costs,
including absence from work and premature death, had contributed to the
overall high cost of treatment.

Competitive Landscape

The market appears to be fairly concentrated and with the presence of
limited vendors. This market research report will help clients identify
new growth opportunities and design unique growth strategies by
providing a comprehensive analysis of the market's competitive landscape
and offering information on the products offered by companies.

Key Players

• AstraZeneca
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
  
• Merck & Co. Inc.

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 07: MARKET SEGMENTATION BY TYPE

• Comparison by type
• Uterine cancer - Market size and forecast 2018-2023
• Ovarian cancer - Market size and forecast 2018-2023
• Cervical cancer - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY PRODUCT

• Targeted therapy
• Vaccination

PART 10: GEOGRAPHIC LANDSCAPE

• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 15: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
  
• Merck & Co. Inc.

For more information about this report visit https://www.researchandmarkets.com/research/kk5cgn/global?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190320005412/en/